Expanded Access to Tipifarnib

Kura Oncology

Status

Conditions: HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

Treatments: Drug: Tipifarnib

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT04809233

Expanded Access to Tipifarnib

Details and patient eligibility

About

Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).

To request access, use Responsible Party contact information provided in this record.

Expanded access for tipifarnib is only available in the United States.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion/Exclusion Criteria:

Diagnosed with HRAS-mutant carcinomas or peripheral T Cell Lymphoma (PTCL).

Adult, ages 18+.

Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.

Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.

Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology